Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes
The pharmacological actions of most antidepressants are ascribed to the modulation of serotonergic and/or noradrenergic transmission in the brain. During therapeutic treatment for major depression, fluoxetine, one of the most commonly prescribed selective serotonin reuptake inhibitor (SSRI) antidepressants, accumulates in the brain, suggesting that fluoxetine may interact with additional targets. In this context, there is increasing evidence that astrocytes are involved in the pathophysiology of major depression.
The aim of this study was to examine the effects of fluoxetine on the expression of neurotrophic/growth factors that have antidepressant properties and on glucose metabolism in cultured cortical astrocytes.
Treatment of astrocytes with fluoxetine and paroxetine, another SSRI antidepressant, upregulated brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and VGF mRNA expression. In contrast, the tricyclic antidepressants desipramine and imipramine did not affect the expression of these neurotrophic/growth factors. Analysis of the effects of fluoxetine on glucose metabolism revealed that fluoxetine reduces glycogen levels and increases glucose utilization and lactate release by astrocytes. Similar data were obtained with paroxetine, whereas imipramine and desipramine did not regulate glucose metabolism in this glial cell population. Our results also indicate that the effects of fluoxetine and paroxetine on glucose utilization, lactate release, and expression of BDNF, VEGF, and VGF are not mediated by serotonin-dependent mechanisms.
These data suggest that, by increasing the expression of specific astrocyte-derived neurotrophic factors and lactate release from astrocytes, fluoxetine may contribute to normalize the trophic and metabolic support to neurons in major depression.
KeywordsAntidepressants Growth factors Glia Serotonin Lactate Glycogen
The authors are grateful to Cendrine Barrière Borgioni and Evelyne Ruchti for valuable technical assistance. This work was supported by the Swiss National Science Foundation grants 31003A-124783 (to JLM) and 3100AO-108336/1 (to PJM), the Désirée and Niels Yde's Foundation (to JLM and PJM), and the Swiss Academy of Medical Sciences (to JLM and PJM). The authors have no financial relationship with the Swiss National Science Foundation, the Désirée and Niels Yde's Foundation, and the Swiss Academy of Medical Sciences. All experiments comply with the Swiss federal act on animal protection and the Swiss animal protection ordinance.
- Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S (2007) Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 321:148–157PubMedCrossRefGoogle Scholar
- Magistretti PJ (2008) Brain energy metabolism. In: Squire LR, Berg D, Bloom FE, Du Lac S, Ghosh A, Spitzer NC (eds) Fundamental neuroscience, 3rd edn. Academic Press, San Diego, pp 271–293Google Scholar
- Magistretti PJ, Sorg O, Martin JL (1993) Regulation of glycogen metabolism in astrocytes: physiological, pharmacological, and pathological aspects. In: Murphy S (ed) Astrocytes: pharmacology and function. Academic Press, San Diego, pp 243–265Google Scholar